The analysis of survival data: the Kaplan Meier method Kitty J. Jager¹, Paul van Dijk 1,2, Carmine Zoccali 3 and Friedo W. Dekker 1,4 1 ERA–EDTA Registry,

Slides:



Advertisements
Similar presentations
Measures of effect: relative risks, odds ratios, risk difference and number needed to treat Giovanni Tripepi, Kitty J. Jager 1, Friedo W. Dekker 1,2, Christoph.
Advertisements

Measures of Disease Occurrence Kitty J. Jager¹, Carmine Zoccali², Reinhard Kramar³ and Friedo W. Dekker 1,4 1 ERA–EDTA Registry, Dept. of Medical Informatics,
The valuable contribution of observational studies to nephrology Kitty J. Jager¹, Vianda S. Stel¹, Christoph Wanner², Carmine Zoccali³ and Friedo W. Dekker.
The analysis of survival data in nephrology. Basic concepts and methods of Cox regression Paul C. van Dijk 1-2, Kitty J. Jager 1, Aeilko H. Zwinderman.
Confounding: what it is and how to deal with it Kitty J. Jager¹, Carmine Zoccali 2, Alison MacLeod 3 and Friedo W. Dekker 1,4 1 ERA–EDTA Registry, Dept.
The randomized clinical trial: an unbeatable standard in clinical research? Vianda S. Stel¹, Kitty J. Jager¹, Carmine Zoccali², Christoph Wanner³, Friedo.
Agreement between Methods Karlijn J. van Stralen¹, Kitty J. Jager¹, Carmine Zoccali², and Friedo W. Dekker 1,3 1 ERA–EDTA Registry, Dept. of Medical Informatics,
What is Event History Analysis?
SURVIVAL AND LIFE TABLES
Measures of disease frequency (II). Calculation of incidence Strategy #2 ANALYSIS BASED ON PERSON-TIME CALCULATION OF PERSON-TIME AND INCIDENCE RATES.
What is Event History Analysis?
Survival Analysis. Key variable = time until some event time from treatment to death time for a fracture to heal time from surgery to relapse.
1 Epidemiologic Measures of Association Saeed Akhtar, PhD Associate Professor, Epidemiology Division of Epidemiology and Biostatistics Aga Khan University,
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
Survival Analysis-1 In Survival Analysis the outcome of interest is time to an event In Survival Analysis the outcome of interest is time to an event The.
This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used for non-commercial study and educational.
Survival Analysis. Statistical methods for analyzing longitudinal data on the occurrence of events. Events may include death, injury, onset of illness,
Analysis of Time to Event Data
Intermediate methods in observational epidemiology 2008 Instructor: Moyses Szklo Measures of Disease Frequency.
Main Points to be Covered
Lecture 3 Survival analysis. Problem Do patients survive longer after treatment A than after treatment B? Possible solutions: –ANOVA on mean survival.
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.
Introduction to Survival Analysis PROC LIFETEST and Survival Curves.
Main Points to be Covered Cumulative incidence using life table method Difference between cumulative incidence based on proportion of persons at risk and.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
EVIDENCE BASED MEDICINE
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Analysis of Complex Survey Data
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Introduction to Survival Analysis August 3 and 5, 2004.
Kidney Transplant: A Realistic Chance for Elderly Patients Reference: Munnapradist S, Danovitch GM. Kidney transplants for the elderly: Hope or hype? Clin.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
1 Survival Analysis Biomedical Applications Halifax SAS User Group April 29/2011.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Lecture 3 Survival analysis.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Design and Analysis of Clinical Study 11. Analysis of Cohort Study Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
INTRODUCTION TO SURVIVAL ANALYSIS
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Lecture 5: The Natural History of Disease: Ways to Express Prognosis
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
12/20091 EPI 5240: Introduction to Epidemiology Incidence and survival December 7, 2009 Dr. N. Birkett, Department of Epidemiology & Community Medicine,
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival.
01/20151 EPI 5344: Survival Analysis in Epidemiology Quick Review from Session #1 March 3, 2015 Dr. N. Birkett, School of Epidemiology, Public Health &
The Databases: Successes and Shortcomings in Renal Replacement Therapy Since 1989 European Renal Association and European Dialysis and Transplant Association.
Some survival basics Developments from the Kaplan-Meier method October
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
SURVIVAL ANALYSIS PRESENTED BY: DR SANJAYA KUMAR SAHOO PGT,AIIH&PH,KOLKATA.
Carolinas Medical Center, Charlotte, NC Website:
An introduction to Survival analysis and Applications to Predicting Recidivism Rebecca S. Frazier, PhD JBS International.
April 18 Intro to survival analysis Le 11.1 – 11.2
UK Renal Registry 10th Annual Report 2007
Volume 55, Issue 4, Pages (April 1999)
Summary of the 2013 ERA-EDTA Registry Annual Report
UK Renal Registry 18th Annual Report
INDIRECT STANDARDIZATION BY MBBSPPT.COM
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Measures of Disease Occurrence
Volume 74, Issue 8, Pages (October 2008)
The analysis of survival data: the Kaplan–Meier method
Chapter 4 SURVIVAL AND LIFE TABLES
Where are we?.
Dialysis outcomes in Australia & New Zealand
Kaplan-Meier survival curves and the log rank test
Figure Prevalence of coronary artery disease by year or
Presentation transcript:

The analysis of survival data: the Kaplan Meier method Kitty J. Jager¹, Paul van Dijk 1,2, Carmine Zoccali 3 and Friedo W. Dekker 1,4 1 ERA–EDTA Registry, Dept. of Medical Informatics, Academic Medical Center, Amsterdam, The Netherlands 2 Department of Clinical Epidemiology, Biostatistics and Bio-informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands 3 CNR–IBIM Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Renal and Transplantation Unit, Ospedali Riuniti, Reggio Cal., Italy 4 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands Kidney International: ABC on epidemiology

Survival analysis Aim: modeling and analysis of time-to-event data Events may include all kinds of positive or negative events Single and combined endpoints This presentation includes a first introduction to survival analysis techniques

Events versus censored data At the end of the follow-up period the event will probably not have occurred for all patients. For those patients survival time is censored. Censoring: we do not know when or whether such a patient will experience the event of interest, only that he or she has not done so by the end of the observation period. Censoring occurs at the end of the observation period, at loss to follow-up or at the occurrence of a competing event. Example 1 – Survival time on RRT: events and censored observations. Incident RRT patients in the ERA-EDTA Registry were included in an analysis of patient survival on RRT. Like in most survival studies patients were recruited over a period of time ( the inclusion period) and they were observed up to a specific date (31 December the end of the follow-up period). During this period the event of interest was death while on RRT, whereas censoring took place at recovery of renal function, loss to follow-up and at 31 December 2005.

The incidence rate of death Figure: Survival times of eight patients at risk of death on RRT. The inclusion period was , whereas follow-up was ended on 31 December 2005.

Assumptions related to censoring At any time patients who are censored have the same survival prospects as those who continue to be followed. –This sometimes is problematic: e.g. in the calculation of survival on dialysis censoring at the time of transplantation is needed because these patients are no longer at risk of death on dialysis – however dialysis patients on the transplant waiting list do not have the same prospects as dialysis patients who are not on the waiting list Survival probabilities are assumed to be the same for subjects recruited early and late in the study. –May test this by splitting a cohort of patients in those who were recruited early and those recruited late and see if their survival curves are different.

Kaplan Meier method Observed survival times were first sorted in ascending order, starting with the patient with the shortest survival time and presented in a table. Example 2 - Survival probability in RRT patients due to diabetes mellitus and other causes In a sample of 50 RRT patients taken from a study on diabetes mellitus survival time started running at the moment a patient was included in the study, in this case at the start of RRT. Patients were followed until death or censoring. The survival probability was calculated using the Kaplan Meier method. Subsequently, the survival of patients with ESRD due to diabetes mellitus was compared to the survival of those with ESRD due to other causes. Used to estimate survival probabilities and to compare survival of different groups.

Kaplan Meier method At the start of the study all 50 patients were alive - proportion surviving and cumulative survival were 1.00 When the first patient died on day 34 after the start of RRT, the proportion surviving was 49/50 = = 98%. To calculate the cumulative survival this proportion surviving was multiplied by the 1.0 cumulative survival from the previous step resulting in a cumulative survival dropping to When the second patient died at day 35, the proportion surviving was 48/49 = To obtain the cumulative survival at day 35, again, this proportion was multiplied by the cumulative survival from the previous step which resulted in a cumulative survival dropping that day to On day 57, however, a patient was withdrawn alive from the study (censored). The proportion surviving that day was 47/47 = 1.00, as this patient did not die but was withdrawn alive from the study. As a result the cumulative survival did not drop that day but remained unchanged at Time in days Number at risk DeathsWithdrawn alive (censored) Proportion surviving on this day Cumulative survival Cumulative mortality /50 = /49 = /48 = …....

Kaplan Meier method Cumulative survival is a probability of surviving the next period multiplied by the probability of having survived the previous period All subjects at risk - also those not experiencing the event during the observation period - can contribute survival time to the denominator of the incidence rate By censoring one is able to reduce the number of persons alive without affecting the cumulative survival

Kaplan Meier method The median survival is that point in time, from the time of inclusion, when the cumulative survival drops below 50%, in this case it is 1708 days Is not related to the number of deaths or the number of subjects that is still at risk Why mean survival is used less frequently: –Survival data mostly highly skewed –In case of censoring one does not know if and when the person will experience the event – this complicates the calculation of the mean –In order to calculate a mean survival one would need to wait until all persons experienced the event Time in days Number at risk DeathsWithdrawn alive (censored) Proportion surviving on this day Cumulative survival Cumulative mortality /50 = /49 = /48 = … /18 = /17 =

Logrank test Most popular method of comparing the survival of groups Takes the whole follow-up period into account Addresses the hypothesis that there are no differences between the populations being studied in the probability of an event at any time point P = 0.04

What the Kaplan Meier method and the logrank test can and cannot do Together the Kaplan Meier method and the logrank test provide an opportunity to: –Estimate survival probabilities and –Compare survival between groups However –One cannot adjust for confounding variables – no mutlivariate analysis –They do not provide an estimate of the effect size and the relating confidence interval In those cases one needs a regression technique like the Cox proportional hazards model